A Review of Remdesivir for COVID-19: Data to Date

被引：5

作者：

Mehta, Monica ^{[1
]}

Shyh, Grace I. ^{[1
]}

机构：

[1] New York Presbyterian Hosp, Dept Pharm, 170 William St, New York, NY 10034 USA

来源：

CARDIOLOGY IN REVIEW | 2020年 / 28卷 / 06期

关键词：

COVID-19; 2019-nCoV; SARS-CoV-2; remdesivir;

D O I：

10.1097/CRD.0000000000000337

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Severe acute respiratory coronavirus-2 (SARS-CoV-2) is responsible for one of the greatest public health challenges of our lifetime, the coronavirus disease 2019 (COVID-19) pandemic. Because of the complicated postinfection sequelae and grave consequences, the search for effective therapies has become a worldwide priority. The antiviral agent remdesivir has become a viable option and is now available in the United States for hospitalized patients through an emergency use authorization. This article describes remdesivir's historical background, pharmacology, key trials, adverse events, and issues regarding accessibility.

引用

页码：332 / 334

页数：3

共 17 条

[1]

Amin T, COVID 19 HAS EXPOSED

[2] Remdesivir for the Treatment of Covid-19-Preliminary Report [J].

Gillenwater, Samantha ;

Rahaghi, Franck ;

Hadeh, Anas .

NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (10) :992-992

[3]

Bhimraj A, INFECT DIS SOC AM GU

[4] An interactive web-based dashboard to track COVID-19 in real time [J].

Dong, Ensheng ;

Du, Hongru ;

Gardner, Lauren .

LANCET INFECTIOUS DISEASES, 2020, 20 (05) :533-534

[5] Remdesivir for 5 or 10 Days in Patients with Severe Covid-19 [J].

Goldman, Jason D. ;

Lye, David C. B. ;

Hui, David S. ;

Marks, Kristen M. ;

Bruno, Raffaele ;

Montejano, Rocio ;

Spinner, Christoph D. ;

Galli, Massimo ;

Ahn, Mi-Young ;

Nahass, Ronald G. ;

Chen, Yao-Shen ;

SenGupta, Devi ;

Hyland, Robert H. ;

Osinusi, Anu O. ;

Cao, Huyen ;

Blair, Christiana ;

Wei, Xuelian ;

Gaggar, Anuj ;

Brainard, Diana M. ;

Towner, William J. ;

Munoz, Jose ;

Mullane, Kathleen M. ;

Marty, Francisco M. ;

Tashima, Karen T. ;

Diaz, George ;

Subramanian, Aruna .

NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (19) :1827-1837

[6] Li Wenliang Obituary [J].

Green, Andrew .

LANCET, 2020, 395 (10225) :682-682

[7]

Hinton D, 2020, FOOD DRUG ADM FDA IS

[8] A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics [J].

Mulangu, Sabue ;

Dodd, Lori E. ;

Davey, Richard T., Jr. ;

Mbaya, Olivier Tshiani ;

Proschan, Michael ;

Mukadi, Daniel ;

Manzo, Mariano Lusakibanza ;

Nzolo, Didier ;

Oloma, Antoine Tshomba ;

Ibanda, Augustin ;

Ali, Rosine ;

Coulibaly, Sinare ;

Levine, Adam C. ;

Grais, Rebecca ;

Diaz, Janet ;

Lane, H. Clifford ;

Muyembe-Tamfum, Jean-Jacques ;

Sivahera, Billy ;

Camara, Modet ;

Kojan, Richard ;

Walker, Robert ;

Dighero-Kemp, Bonnie ;

Cao, Huyen ;

Mukumbayi, Philippe ;

Mbala-Kingebeni, Placide ;

Ahuka, Steve ;

Albert, Sarah ;

Bonnett, Tyler ;

Crozier, Ian ;

Duvenhage, Michael ;

Proffitt, Calvin ;

Teitelbaum, Marc ;

Moench, Thomas ;

Aboulhab, Jamila ;

Barrett, Kevin ;

Cahill, Kelly ;

Cone, Katherine ;

Eckes, Risa ;

Hensley, Lisa ;

Herpin, Betsey ;

Higgs, Elizabeth ;

Ledgerwood, Julie ;

Pierson, Jerome ;

Smolskis, Mary ;

Sow, Ydrissa ;

Tierney, John ;

Sivapalasingam, Sumathi ;

Holman, Wendy ;

Gettinger, Nikki ;

Vallee, David .

NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (24) :2293-2303

[9]

National Center for Biotechnology Information, PUBCHEM DAT REMD CID

[10]

NIH National Institutes of Health, COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines

← 1 2 →